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Summary
Genetic analysis of familial Alzheimer’s disease has re-
vealed that mutations in theg-secretase enzyme prese-
nilin promote toxic Ab secretion; however, presenilin
mutations might also influence tau hyperphosphory-
lation and neurodegeneration through g-secretase-
independent mechanisms. To address this possibility
and determine whether other components of the g-sec-
retase complex possess similar regulatory functions,
we analyzed the roles of presenilin, nicastrin, and
aph-1 in a Drosophila model for tau-induced neurode-
generation. Here, we show that presenilin and nicastrin
prevent tau toxicity by modulating the PI3K/Akt/GSK3b
phosphorylation pathway, whereas aph-1 regulates
aPKC/PAR-1 activities. Moreover, we found that these
transmembrane proteins differentially regulate the
intracellular localization of GSK3b and aPKC at cell
junctions. Inhibition of g-secretase activity neither in-
terfered with these kinase pathways nor induced aber-
rant tau phosphorylation. These results establish new
in vivo molecular functions for the three components
of theg-secretase complex and reveal a different mech-
anism that might contribute to neuronal degeneration
in Alzheimer’s disease.
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Abnormal protein aggregation is a common characteris-
tic of many neurodegenerative disorders. Alzheimer’s
disease (AD) is a classic example in which brains of af-
fected individuals exhibit extracellular accumulation of
Ab peptide because of aberrant proteolytic cleavage of
the membrane bound amyloid precursor protein (APP)
(Price et al., 1998) as well as intracellular aggregates of
abnormally phosphorylated tau (Lee et al., 2001).
Genetic analysis of early onset familial AD (FAD) has
revealed that the pathological accumulation of Ab is
due to mutations in APP or in the APP-cleavage enzyme
presenilin (Price and Sisodia, 1998), resulting in increased
production of the more amyloidogenic Ab forms, termed
Ab1-42 (Tanzi and Bertram, 2001). Affected individuals
also exhibit neurofibrillary tangles (NFT), leading to the
proposal that Ab peptide accumulation triggers tau
hyperphosphorylation and neuronal death in AD (Hardy
and Selkoe, 2002). Consistent with this idea, the induction
of amyloid deposits in transgenic mice precedes and
promotes NFT formation (Gotz et al., 2001; Lewis et al.,
2001; Oddo et al., 2003), whereas immunotherapeutic
or pharmacological clearance of amyloid plaques sup-
presses early-stage tau lesions (Oddo et al., 2004). More-
over, neurons from mice lacking tau are insensitive to
b-amyloid-mediated toxicity (Rapoport et al., 2002).
Although there is a large body of evidence supporting
the amyloid cascade in Alzheimer’s disease (Hardy and
Selkoe, 2002; Price et al., 1998; Scheuner et al., 1996;
St George-Hyslop and Petit, 2005; Tanzi and Bertram,
2005), the neurodegeneration typical of this disease
can occur independently of extracellular amyloid. Cer-
tain cases of FAD are characterized by abundant NFT
in the absence of amyloid plaques (Dermaut et al.,
2004), suggesting that increased Ab secretion may not
be the only contributing factor to the onset of disease.
In support of this view are the neurological phenotypes
observed in presenilin 1 and presenilin 2 brain-specific
conditional knockout mice. These animals exhibit mem-
ory defects, synaptic dysfunction, increased tau phos-
phorylation, and neurodegeneration without amyloid
production (Feng et al., 2004; Saura et al., 2004). Thus,
at least some cases of dementia could be due to aber-
rant tau phosphorylation induced by presenilin malfunc-
tion. In this scenario, presenilin, alone or as part of the
g-secretase complex with nicastrin, aph-1 and pen-2
(De Strooper, 2003), might regulate the intracellular
phosphorylation pathways that converge upon tau.
Indeed, recent work has shown that presenilin promotes
cadherin/PI3K recruitment and prevents GSK3b-medi-
ated tau phosphorylation in vitro (Baki et al., 2004). It is
not known, however, whether a similar mechanism influ-
ences tau toxicity in vivo or what role other g-secretase
components play in tau-induced neurodegeneration. To
address these questions, we examined the effects of
gene dosage alterations in presenilin (psn), nicastrin
(nct), and aph-1 with a Drosophila transgenic model
for tau-induced neurodegeneration (Jackson et al.,
2002; Wittmann et al., 2001).
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Reduced Presenilin Function In Vivo Leads to Tau
Hyperphosphorylation and Neurodegeneration
Compared to the wild-type fly eye, expression of htau
under the eye-specific promoter glass (hereafter gl-htau)
produces a mild disorganization of the retina that is
evident as a roughened exterior eye surface (Figures 1A
and 1B) (Jackson et al., 2002). This phenotype is dra-
matically enhanced when one copy of presenilin (psn)
is removed, as found with two different null alleles of
psn (Figures 1C and 1D) (Ye et al., 1999). Eyes are sig-
nificantly reduced in size, and fused or disordered
ommatidia cover >80% of the eye surface. Longitudinal
sections labeled with the photoreceptor-specific anti-
body 24B10 (Zipursky et al., 1984) revealed that expres-
sion of htau alone leads to mild disorganization of the
internal retinal morphology (Figures 1F and 1G), where-
as the retinas of gl-htau/psnB3 and psnC4 heterozygous
flies displayed dramatic defects including reduced
photoreceptor layer depth, decomposition of the base-
ment membrane, and increased neuronal cell loss (Fig-
ures 1H and 1I).
To determine if these cellular defects correlated with
abnormal modification of tau, we analyzed tau phos-
phorylation status in gl-htau/psn flies. Western blotting
of Drosophila head extracts with AT8 and 12E8 anti-
bodies, which detect two distinct AD-related tau epi-
topes, revealed that reduction in psn increases AT8 but
not 12E8 signal (Figure 1K). Reactivity to antibodies
PHF1 and AT100, which recognize abnormally phos-
phorylated tau in pretangle paired helical filaments and
fully formed neurofibrillary tangles, respectively, (Seu-
bert et al., 1995; Hernandez et al., 2003; Lovestone
et al., 1994; Lucas et al., 2001), revealed a dramatic in-
crease in tau phosphorylation at these epitopes as well
(Figure 1K). To confirm these differences in the phos-
phorylation pattern of tau, we analyzed each genotype
by an immunocytochemical approach. Tangential sec-
tions of adult retinas labeled with the 7.51 antibody
against total tau did not reveal any modifications in tau
expression when one copy of psn was removed (Figures
S1D–S1F). In contrast, the AT100 antibody epitope
showed dramatic changes in intensity and distribution
(Figures S1A–S1C), confirming that htau is abnormally
modified when psn function is genetically reduced. To
examine whether these modifications affect htau intra-
cellular solubility, we performed sarcosyl extractions to
monitor levels of filamentous tau. Compared to control
gl-htau flies, tau is more insoluble in psn heterozygous
flies (Figure 1L), suggesting that htau undergoes alter-
ations similar to those observed in AD.
To prove that the changes in tau phosphorylation were
a consequence of psn loss and not due to genetic back-
ground effects, we performed a genetic rescue experi-
ment by expressing full-length psn under the GMR
promoter (Ye and Fortini, 1999) in gl-htau/psnB3 transhe-
terozygous flies. This ectopic psn expression largely
suppressed the htau-mediated neurodegeneration (Fig-
ures 1E and 1J) and reduced htau phosphorylation levels
at the AT8, AT100, and PHF1 sites (Figure 1M). Thus,
endogenous levels of psn are required to prevent
abnormal tau phosphorylation in vivo. Intriguingly, the
data suggest that the psn regulatory effect is specific
RE
TRfor certain phosphorylation pathways, as reflected by
the absence of increased 12E8 immunoreactivity (Fig-
ure 1K), rather than a global upregulation of tau kinase
activities.
Tau Hyperphosphorylation Induced by Presenilin
Reduction Requires GSK3b but Not PAR-1 Activity
Abnormal phosphorylation of tau at the AT8, PHF1, and
AT100 epitopes in psn heterozygous flies suggests that
GSK3b might be the kinase regulated by psn. Previous
in vitro studies showed that psn regulates GSK3bactivity
and prevents tau hyperphosphorylation through activa-
tion of the PI3K/Akt pathway (Baki et al., 2004). We there-
fore analyzed whether mutations in psn increase the
activity of shaggy, the Drosophila homolog of human
GSK3b (Siegfried et al., 1992), and whether mutations
in this kinase suppress psn-induced tau toxicity. First,
we expressed shaggy with the eye-specific GMR pro-
moter (GMR-UAS-sgg) (Jackson et al., 2002; Nishimura
et al., 2004), which produces a mild retinal degeneration
phenotype (Figure 2A; see Figure 1A for comparison).
This phenotype was strongly enhanced by removal of
one copy of psn, suggesting that the activity of the
shaggy kinase was further increased (Figure 2B). We
monitored the phosphorylation status of shaggy under
different psn gene dosages with phospho-specific anti-
bodies that recognize either the phospho-tyrosine-216
residue (anti-GSK3b-pY216) in the active kinase (Figures
S2A and S2B) or the phosphorylated inhibitory serine-9
residue (anti-GSK3b-pS9) (Matsubayashi et al., 2004;
Nusse, 1997). An increase in shaggy activation was
observed in heterozygous psn flies compared to wild-
type (Figure 2F, anti-GSK3b-pY216 antibody). A concom-
itant decrease was detected at the inhibitory serine-9
epitope (data not shown). Removing one copy of psn in
GMR-UAS-sgg flies led to a dramatic reduction in the
GSK3b-pS9 signal, confirming the increased activation
of shaggy in the psn heterozygous background (Fig-
ure 2F). Rescue experiments corroborated the role of
psn in regulating shaggy activity as shown by suppres-
sion of the GMR-UAS-sgg phenotype upon psn trans-
gene expression (Figures 2B and 2C). Transgenic psn
expression also elevated shaggy phosphorylation on in-
hibitory serine-9 and reduced signal at the GSK3b-pY216
site in the activation loop (Figure 2F), demonstrating that
psn inhibits shaggy activation.
Next, we analyzed whether reducing shaggy activity
suppresses psn-induced neurodegeneration. Removing
one copy of shaggy from gl-htau/psn transheterozygous
flies suppressed the psn mutation-induced enhance-
ment of the gl-htau eye phenotype (Figure 2D; compare
to Figures 1C and 1D and see Figure S3A for quantitative
analysis). The psn transheterozygous flies lacking one
dose of shaggy showed significant reductions in tau
phosphorylation at the cytotoxic epitopes AT100 and
PHF1 (Figure 2G). On the other hand, removing one
copy of PAR-1, the kinase responsible for tau phosphor-
ylation at the 12E8 epitope (Nishimura et al., 2004), did
not ameliorate the effects of the psn mutation (Fig-
ure 2E), indicating that psn regulation of shaggy is spe-
cific. We also explored whether Akt (the specific kinase
for the serine-9 epitope) and its activator PI3K are in-
volved in the psn/shaggy/tau phosphorylation pathway
in vivo. We reasoned that if this is the case, lower activity
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361Figure 1. Gene Dosage Reductions in Presenilin Enhance Tau-Mediated Neurodegeneration and Hyperphosphorylation
(A–E) Light microscope images of a wild-type fly eye (A) and transgenic eyes expressing w; gl-htau/+ (B) or gl-htau/+ in transheterozygous
combinations with psn alleles: w; gl-htau/+; psnB3/+ (C) and w; gl-htau/+; psnC4/+ (D) or with psn function restored by a transgene in w;
gl-htau/GMR-psnwt; psnB3/+ (E).
(F–J) Immunolabeling of photoreceptor neurons with the 24B10 antibody. Genotypes (as in [A]–[E]) are wild-type (F), w; gl-htau/+ (G), w; gl-htau/+;
psnB3/+ (H), w; gl-htau/+; psnC4/+ (I), and gl-htau/GMR-UAS-psnwt; psnB3/+ (J). Long arrows demarcate the longitudinal extent of the retina; small
arrows denote the basement membrane separating retina from optic ganglia.
(K) Western blot analyses of htau phosphorylation in a psn heterozygous mutant background (gl-htau/psnB3) demonstrating increases at the AT8,
PHF1, and AT100, but not 12E8 epitopes compared to control gl-htau flies. Immunoblotting with 7.51 antibody against total htau confirms equal
sample loading.
(L) Sarcosyl-insoluble tau levels in gl-htau transgenic flies with reduced gene dosages of individual g-secretase components in head homoge-
nates probed with the 7.51 antibody.
(M) Suppression of psn mutant-induced htau hyperphosphorylation by transgenic psn expression. Expression of psn under GMR-GAL4 control in
w; gl-htau/+; GMR-UASpsn+14/psnB3 reduces tau phosphorylation at AT8, AT100, and PHF1 epitopes compared to w; gl-htau/+; psnB3/+ flies.
Antibody 7.51 was used as the loading control. Histograms represent quantitative analysis of the corresponding blots in (K)–(M). Scale bars: (A–E),
100 mm; (F–J), 20 mm. Mean 6 SEM, p < 0.001.
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363of the PI3K/Akt pathway should increase tau toxicity,
whereas exogenous PI3K/Akt expression might sup-
press the neurodegeneration caused by psn gene
dose defects. As predicted, expression of a dominant-
negative form of PI3K or removal of one copy of Akt in-
creased tau-mediated neurotoxicity (Figures 2H and 2I;
compare to Figure 1B and see Figure S3B for quantifica-
tion). Conversely, ectopic expression of PI3K and Akt
transgenes dramatically suppressed the phenotype
induced by heterozygosity for psn (Figures 2J and 2K;
Figure 1C for comparison) as well as hyperphosphoryla-
tion of htau (Figure 2L). In addition, probing the phos-
phorylation status of Akt at serine-473, a site modulated
by PI3K (Baki et al., 2004), revealed that it is underphos-
phorylated in psn heterozygous flies, suggesting that
psn is required for full activation of the PI3K/Akt path-
way (Figure 2M). Taken together, our results show that
psn counteracts tau phosphorylation in vivo through
the PI3K/Akt/GSK3b pathway.
Our third experimental approach toward understand-
ing how psn controls shaggy/GSK3b activity in vivo in-
volves examining the spatial distribution of the kinase
in the presence or absence of psn. Relocalization of the
shaggy kinase from the membrane to the cytoplasm
might be indicative of its differential modulation in certain
genotypes, with implications for tau phosphorylation. In
wild-type third instar larval imaginal eye discs, shaggy la-
beling is most evident in discrete vesicles close to the cell
cortex in both neurons and epithelial cells. In contrast, in
psn homozygous mutant eye clones, the kinase adopts
a much more diffuse, intracytoplasmic distribution (Fig-
ures 2N and 2O). We determined that the intracellular dis-
tribution of the Drosophila b-catenin homolog armadillo
(another substrate of shaggy) was not affected by psn
mutations (Figures 2P and 2Q), indicating that the effect
observed on shaggy localization is specific and cannot
be attributed to a general defect in cell survival or apico-
basal polarity.
The Regulation of Tau Kinase Pathways Does Not
Require the Aspartyl Protease Function of Presenilin
To explore the relevance of our findings to AD, we exam-
ined whether familial Alzheimer’s disease (FAD)-linked
mutations interfered with the regulatory effects of psn
described above. Toward this aim, we analyzed the
TR
Acapacity of a psn FAD mutant allele with a deletion in
exon 9 (psnDE9) to suppress the enhanced tau toxicity in-
duced by loss of one copy of psn. Two different insertions
of the psnDE9 FAD mutation expressed under the GMR
promoter failed to rescue the gl-htau/psn phenotype
compared to the wild-type psn transgene (Figures 3A
and 3B; compare to Figure 1E; Figure S3C for quantifica-
tion). Unexpectedly, analogous expression of catalyti-
cally inactive alleles of psn (Asp-257 or Asp-385) sup-
ports almost complete rescue of the psn-induced
neurodegeneration (Figures 3C and 3D). These different
outcomes were verified at the molecular level for the rel-
evant kinases. Compared to the psn wild-type allele,
psnDE9 failed to promote Akt phosphorylation or to
phosphorylate shaggy at the Akt-specific epitope ser-
ine-9 and also did not prevent tau hyperphosphorylation
(Figure 3E). However, the catalytically inactive psn alleles
activate the PI3K/Akt pathway and suppress tau phos-
phorylation as efficiently as wild-type (Figure 3E). These
data suggest that FAD mutations in psn may promote
tau hyperphosphorylation by g-secretase-independent
mechanisms.
To further test this idea, we suppressed g-secretase
activity by exposing gl-htau-expressing flies to well-char-
acterized g-secretase inhibitors throughout develop-
ment. To confirm that the drugs effectively blocked psn
aspartyl protease activity, we utilized a transgenic read-
out to assess g-secretase cleavage in vivo. This system
relies on a transmembrane form of human APP (C99)
fused to the transcriptional activator GAL4-VP16 (GV),
which induces expression of a nuclear UAS-cd8-GFP re-
porter gene after intramembrane g-secretase cleavage of
the C99-GAL4-VP16 fusion (Struhl and Adachi, 2000).
These flies, also bearing the gl-htau transgene (referred
to as gl-htau/Ab-GV, UAS-cd8-GFP), exhibit robust g-
secretase-dependent expression of GFP (Figure 3F; see
Experimental Procedures). When treated with the g-sec-
retase inhibitorDAPT (Micchelli et al., 2003), their GFP sig-
nal was strongly reduced (Figure 3G). Similar effects were
obtained with a second g-secretase inhibitor, Compound
E (data not shown). Western blot analysis of extracts from
DAPT/Compound E-treated and untreated gl-htau/Ab-
GV, UAS-cd8-GFP fly heads revealed that g-secretase
inhibition had no effect on tau phosphorylation or the
activation status of shaggy (Figure 3H). These results
CT
EDFigure 2. Shaggy Activity Is Regulated by Presenilin and Mediates Tau Toxicity
(A–E) Eye phenotypes of GMR-sgg/wt (A), GMR-sgg /psnB3 (B), GMR-sgg/psnB3; GMR-Psn/+ (C), w/sgg1; gl-htau/+; psnB3/+ (D), and w/par1w3;
gl-htau/+; psnB3/+ (E). The terms GOF (gain of function) and LOF (loss of function) are used as abbreviations for the full genotypes.
(F) Western blot showing that elimination of one copy of psn increased shaggy activity in w; gl-htau/+; psnB3/+ transheterozygous flies, as re-
vealed by increased phosphorylation at the GSK3b-pY216 activation loop epitope (see also Figure S1) and decreased inhibitory phosphorylation
at serine-9 detected by GSK3b-pS9 antibody in psn heterozygous w; +/+; GMR-UAS-sgg/psnB3 flies relative to control w; +/+; GMR-UAS-sgg/+
flies. Conversely, psn transgenic expression antagonizes shaggy activity as revealed by decreased phosphorylation of the activation loop and
increased GSK3b-pS9 signal in w; GMR-UAS-sgg/UAS-psn+14. Tubulin serves as the loading control.
(G) Shaggy is responsible for htau hyperphosphorylation at AT100 and PHF1 epitopes in psn heterozygous flies as deduced by comparing tau
phosphorylation in w; gl-htau/+, w/sgg1; gl-htau/+, w; gl-htau/+; psnB3/+ and w/sgg1; gl-htau/+; psnB3/+ flies. 7.51 antibody was used as the
loading control. Histograms at right show quantitation of phosphorylation levels (n = 3 per genotype).
(H–K) Eye phenotypes of w; gl-htau/+; PI3K LOF/+ (H), w; gl-htau/+; Akt LOF/+ (I), w; gl-htau/+; psnB3/+; GMR-PI3K (J), and w; gl-htau/+; psnB3/+;
GMR-Akt (K).
(L) Suppression of psn mutant-induced htau hyperphosphorylation at the AT8 epitope by transgenic expression of PI3K or Akt.
(M) Reduced psn gene dosage diminishes Akt activity.
(N–O) Confocal analysis of third instar larval eye discs immunolabeled with either the GSK3b-pY216 or armadillo antibody, counterstained with
phalloidin. (N) shaggy/GSK3b is detected predominantly in small, punctate vesicle-like structures at the cell cortex in wild-type neuronal clusters,
whereas it is uniformly distributed in the cytoplasm in psn homozygous mutant clones (O). The subcellular distribution of armadillo is not signif-
icantly altered in psn mutant cells (Q) compared to wild-type (P). Scale bars: (A–E and H–K), 100 mm; (N–Q), 5 mm. Mean 6 SEM, p < 0.001.
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(A–D) Eye phenotypes of w; gl-htau/GMR-psnDE9; psnB3/+ (A), w; gl-htau/+; psnB3/GMR-psnDE9 (B), w/GMR-psnA279DN; psnB3/+ (C), and w;
gl-htau/GMR-psnA447DN; psnB3/+ (D).
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365further confirm a regulatory activity of psn distinct from its
known aspartyl protease function.
Loss-of-Function Mutations in Nicastrin and aph-1
Induce Tau Hyperphosphorylation and
Neurodegeneration
Our previous results indicating that psn possessesg-sec-
retase-independent regulatory capacities toward tau led
us to ask whether other components of the g-secretase
complex exert similar functions. We performed a series
of genetic interaction experiments with null mutations of
nct or aph-1 in conjunction with gl-htau. Figures 4A–4D
show the eye phenotypes produced by removing one
copy of nct or aph-1 in gl-htau expressing flies (see
Figure 1B for control). Two different alleles for nicastrin
(nctA7 and nctJ1) or aph-1 (aph-1D35 and the aph-1 defi-
ciency Df[2L]N6) were utilized for this experiment (Hu
and Fortini, 2003; Hu et al., 2002). From the reduced size
and severely roughened appearance of the eye surface,
it is evident that mutations in either nct or aph-1 strongly
enhance the neurodegenerative phenotype of htau (see
Figure S3D for quantification). To investigate whether
the internal retinal morphology is correlated with the de-
gree of neurodegeneration apparent from the external
eye phenotype, we performed histological analysis.Com-
pared to control flies (see Figure 1G), both nct alleles
enhanced the gl-htau phenotype (Figures 4E and 4F),
whereas aph-1 mutant-induced enhancement of the
phenotype was more modest (Figures 4G and 4H).
To determine if these genetic interactions were ac-
companied by changes in htau phosphorylation, we per-
formed biochemical studies similar to those described
above for psn (cf. Figure 1K). Interestingly, we observed
that heterozygous nct or aph-1 mutations cause different
effects on tau phosphorylation (Figure 4I). Although
both nct and aph-1 hyperphosphorylate tau at the
PHF1 antibody epitope, mutations in nct enhance htau
phosphorylation at the AT8 site, whereas those in aph-
1 preferentially increase phosphorylation at the 12E8
and AT100 sites. These modifications increase the cyto-
plasmic insolubility of tau as reflected by changes
observed in sarcosyl extraction experiments (Figure 1L).
Genetic rescue experiments confirmed the specificity of
these histological and biochemical findings. Expression
of wild-type nct or aph-1 transgenes in gltau/nct or gltau/
aph-1 transheterozygous flies strongly suppressed both
the aberrant retinal phenotypes and the abnormal induc-
tion of tau phosphorylation (Figures 4J–4N). Taken to-
gether, these results demonstrate that reductions in nct
and aph-1, like psn, induce abnormal tau hyperphos-
phorylation and enhancedneurotoxicity.Given that phar-
macological inhibition of g-secretase activity did not
modify the tau phosphorylation pattern, nct and aph-1
also presumably regulate these phosphorylation path-
ways through g-secretase-independent mechanisms.
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through the Shaggy/GSK3b and PAR-1 Signaling
Pathways, Respectively
The biochemical data in Figure 4I suggests that nct and
aph-1 dosage changes result in qualitative differences
with respect to the particular htau phospho-epitopes af-
fected. Heterozygous mutations in nct enhanced htau
phosphorylation at epitopes recognized by the AT8
and PHF1 antibodies, suggesting that, as with psn,
shaggy/GSK3b is the relevant kinase, whereas the aph-
1 mutation resulted in increased phosphorylation at the
PAR-1-specific 12E8 epitope. To determine if these ki-
nases are differentially upregulated in the nct and aph-
1 genotypes, we examined whether reductions in shaggy
or PAR-1 activity suppressed the htau phenotypes pro-
duced by nct and aph-1 gene dose changes. Removing
one copy of shaggy strongly suppressed the phenotype
observed in gl-htau/nct flies (Figure 5A; compare to
Figure 4A). Interestingly, a similar gene-dose reduction
in shaggy failed to suppress the neurodegeneration in-
duced by aph-1 (Figure 5B). Conversely, eliminating
one copy of PAR-1 strongly suppressed this aph-1-asso-
ciated phenotype (Figure 5C; compare to Figure 4C)
without any effect on neurodegeneration induced by
nct (Figure 5D; see Figure S3E for quantification).
To further explore these results, we analyzed whether
nct and aph-1 modulate the activity of shaggy and
PAR1 in vivo. We exogenously expressed these kinases
with the eye-specific GMR promoter, utilizing the GMR-
UAS-sgg transgene (see above) and a GMR-UAS-PAR-1
transgene (Jackson et al., 2002; Nishimura et al., 2004).
A gene-dose reduction in nct strongly enhanced the
phenotype of the shaggy-expressing flies (Figure 5E,
compare to Figure 2A), whereas a similar deficiency in
aph-1 had no effect (Figure 5F). Consistent with these
observations, ectopic expression of the aph-1 transgene
did not rescue the GMR-UAS-sgg/nct heterozygous
phenotype or suppress the effect of shaggy expression
alone (Figure 5G and Figure S3F).
An analogous approach utilizing PAR-1 revealed that
mutations in aph-1 but not nct or psn modified the phe-
notype produced by expression of this kinase. GMR-
UAS-PAR-1-expressing flies display a rough eye pheno-
type characterized by the absence of interommatidial
bristles, a glazed eye surface, and a mild reduction in
eye size (Figure 5I). When one copy of aph-1 was re-
moved from this genetic background, the eye phenotype
was dramatically enhanced, as evinced by the severely
reduced size of the eye (Figure 5J). A similar phenotype
was observed with the aph-1 deficiency (data not
shown). In contrast to aph-1, heterozygous mutations
in nct or psn failed to modify the PAR-1 expression phe-
notype (Figures 5K and 5L). Consistent with these find-
ings, expression of nct or psn transgenes was unable
to rescue the aph-1 dosage effect on this PAR-1-induced
CT
ED(E) Western blot analysis showing that psnDE9 does not activate Akt or inhibit GSK3b and is unable to suppress tau hyperphosphorylation at the
AT8 epitope. Tubulin serves as the loading control.
(F–G) gl-htau/Ab-GV, UAS-cd8-GFP transgenic flies treated with DMSO (F) or the g-secretase inhibitor DAPT at a sublethal dose throughout de-
velopment (G), showing GFP signal at 12 hr after heat-shock-induced activation of the Ab-GV construct.
(H) Western blots showing no modification of tau phosphorylation levels (at the AT8, AT100, PHF1, and 12E8 epitopes) or shaggy activation (with
anti-GSK3b-pY216 antibody) after DAPT or Compound E treatment. Antibody 7.51 to total tau was used as the loading control. Scale bars: (A)–(D),
100 mm. Mean 6 SEM, p < 0.001.
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366Figure 4. Mutations in nct and aph-1 Induce Tau Hyperphosphorylation and Neurodegeneration
(A–D) Eye phenotypes of transgenic flies expressing gl-htau and heterozygous for nct or aph-1, as follows: w; gl-htau/+; nctJ1/+ (A), w; gl-htau/+;
nctA7/+ (B), w; gl-htau/aph-1D35 (C), and w; gl-htau/Df(2L)N6 (an aph-1 deficiency) (D).
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367eye phenotype (Figures 5M, 5N, and 5O; see Figure 5J
for comparison).
To validate these genetic interactions at the molecular
level, we analyzed the phosphorylation status of these ki-
nases in the different genotypes. Western blot analysis of
wild-type, nct, and aph-1 heterozygous mutant head ex-
tracts with the anti-GSK3b-pY216 antibody revealed mod-
est yet reproducible increases in activated shaggy in nct
heterozygous flies, but not in aph-1 mutant flies (Fig-
ure 5P). A similar analysis utilizing the anti-GSK3b-pS9 an-
tibody in shaggy-expressing flies showed that mutations
in nct, but not in aph-1, reduced the phosphorylation
levels at the inhibitory serine-9 (Figure 5P). These modifi-
cations were rescued by ectopic expression of the nct
transgene but not the aph-1 transgene, confirming that
nct regulates the activation status of shaggy in vivo.
To evaluate whether mutations in aph-1 increase PAR-
1 activity, we utilized two different approaches. First, we
analyzed the phosphorylation status of PAR-1 at the
conserved inhibitory threonine-595 (PAR-1T595) (Hurov
et al., 2004) (Figure S2C). Second, we analyzed htau
phosphorylation levels at an epitope specifically phos-
phorylated by PAR-1 and recognized by the 12E8 anti-
body. Gene-dose defects in aph-1, but not in nct or
psn, decreased phosphorylation levels of PAR-1 at the
T595 site indicating that the kinase is more active in the
absence of aph-1. This labeling was restored by intro-
duction of the aph-1 transgene, but not by introduction
of nct or psn transgenes (Figure 5Q). In agreement with
these results, aph-1 heterozygous mutant flies exhibited
increased 12E8 reactivity compared to gl-htau control
flies, which was suppressed by the aph-1 transgene
(Figure 4N). Taken together, these results demonstrate
that nct and aph-1 suppress tau hyperphosphorylation
via two distinct pathways involving shaggy/GSK3b and
PAR-1, respectively.
Nicastrin Regulates Shaggy Activity and Tau
Phosphorylation via the PI3K/Akt Pathway
The experiments described above suggested that nct
and psn might share a common regulatory pathway. To
address this possibility, we analyzed whether PI3K or
Akt transgenic expression rescues the phenotype ob-
served in gl-htau/nct heterozygous flies. Increased levels
of PI3K expression completely rescued the toxicity in-
duced by removing one copy of nct (Figure 6A; compare
to Figures 4A and 4B). Furthermore, this effect is strictly
dependent on PI3K activity because a similar attempt,
with a ‘‘kinase dead’’ form of the enzyme, failed to rescue
the phenotype (Figure 6B). As expected, transgenic ex-
pression of two different activating alleles of Akt also
suppressed the nct-mediated tau toxicity (Figures 6C
and 6D).
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nct but not aph-1 decreased the levels of Akt phosphor-
ylation at the residue recognized by PI3K (Figure 6E),
similar to the effect observed earlier for psn (Figure 2M).
Moreover, ectopic expression of either PI3K or Akt led to
a decrease in the level of tau phosphorylation at the
GSK3b-related AT8 epitope (Figure 6F).
In addition, we found that nct is required and sufficient
to maintain the proper localization of shaggy at the cell
cortex. Shaggy is dramatically mislocalized in nct homo-
zygous mutant eye clones compared to wild-type cells
(Figure 6G). In nct mutant cells, shaggy adopted a
more diffuse intracytoplasmic distribution. Although
mutations in nct exhibit severe defects in photoreceptor
differentiation because of impaired Notch signaling and
cytoskeletal assembly (Lo´pez-Schier and St Johnston,
2002), the specificity of the effect on shaggy localization
can be inferred from the unaffected subcellular distribu-
tion of two other cortically distributed proteins, namely
the b-catenin homolog armadillo and the aPKC kinase
(Figures 6H and 6I). An opposing effect was observed
upon expression of the nct transgene; higher levels of
nct expression caused a dramatic accumulation of
shaggy at the cell cortex (Figure 6J), whereas the distri-
bution of PAR-1 was unaffected (Figure 6K). In sum,
these data suggest that nct, like psn, suppresses tau
phosphorylation through the PI3K/Akt/GSK3b pathway
by promoting the proper compartmentalization of
shaggy activity within the cell.
Aph-1 Suppresses Tau Hyperphosphorylation
through the aPKC/PAR-1 Pathway
We have shown above (Figure 5Q) that modifications
in aph-1 expression levels affect the phosphorylation
status of PAR-1 at inhibitory threonine-595, a putative
phosphorylated residue for the atypical phospho-kinase
C (aPKC) (Hurov et al., 2004). To test if aPKC is involved
in aph-1-mediated PAR-1 repression, we analyzed first
whether mutations in this kinase affect tau toxicity.
Two different alleles of aPKC, a heterozygous loss-of-
function mutant (Figure 7A) and a dominant negative
form of the kinase (aPKC-DN) (Figure 7B), enhanced
tau-mediated neurodegeneration. Moreover, the same
aPKC mutants in combination with mutations in aph-1
increased the phenotypic effect on tau toxicity exerted
by any of these single mutations (data not shown). More-
over, the aPKC mutants counteracted the genetic res-
cue of the gl-htau/aph-1phenotype mediated by aph-1
transgenic expression (Figure 7C), further implicating
aPKC in the aph-1 mutant-induced tau toxicity.
To determine whether aph-1 modulates PAR-1 activity
via aPKC, we performed an epistatic analysis with these
genes. A reduction in gene dose levels of aPKC or
CT
ED(E–H) Immunolabeling of photoreceptor neurons using the 24B10 antibody reveals severely altered retinal architecture (large arrows) and disrup-
tions in the basement membrane (small arrows) for the genotypes corresponding to those in A–D.
(I) Western blot analyses of tau phosphorylation in gl-htau/nctJ1 and gl-htau/aph-1D35 flies compared to gl-htau/+ control flies. Histograms
represent quantitation of antibody signal in the blots. Antibody 7.51 serves as the loading control.
(J and K) Expression of functional nct or aph-1 transgenes in the corresponding gl-htau/nctJ1 or gl-htau/aph-1D35 transheterozygous flies par-
tially suppresses their abnormal eye phenotypes (compare to [A]–[D]).
(L and M) Immunolabeling of photoreceptor neurons with the 24B10 antibody reveals that transgenic expression of nct and aph-1 restores a
relatively normal retinal structure (large arrow) to the genotypes shown in (J) and (K).
(N) Western blot analysis demonstrating that transgenic expression of nct or aph-1 suppresses abnormal tau hyperphosphorylation at the AT8
and 12e8 epitopes, respectively, that are observed after reductions in nct or aph-1 levels. 7.51 antibody serves as the loading control. Scale bars:
(A)–(D) and (J)–(K), 100 mm; (E)–(H) and (L)–(M), 20 mm. Mean 6 SEM, p < 0.001.
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368Figure 5. Mutations in nct and aph-1 Increase Shaggy and PAR-1 Activities, Respectively
(A and B) Removing one dose of shaggy from gl-htau/nctJ1 transheterozygous flies strongly suppresses their rough eye phenotype in
w/sgg1; +/+; gl-htau/nctJ1 but does not rescue the aph-1 mutant-induced neurodegeneration in w/sgg1; aph-1D35/+; gl-htau/+ (B).
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369expression of dominant negative aPKC-DN enhanced
the PAR-1 expression phenotype and counteracted the
genetic rescue of the GMR-UAS-PAR-1/aph-1 pheno-
type by aph-1 transgene expression (Figures 7D–7F).
Furthermore, heterozygous mutations in aPKC in-
creased tau phosphorylation levels at the PAR-1-spe-
cific epitope 12E8 and decreased the levels of anti-
pT595-PAR-1 antibody labeling, indicating that PAR-1
was more active (Figures 7G and 7H). From these results,
we infer that aPKC activity is required to mediate the reg-
ulatory effect of aph-1 on PAR-1 function.
To gain more insight into the mechanism through
which aph-1 regulates aPKC and PAR-1, we analyzed
whether aph-1 influences the intracellular localization
of these two kinases. Homozygous aph-1 mutant cell
clones were generated at embryonic stages and the
subcellular distributions of both aPKC and PAR-1 were
evaluated in larval eye discs (see Experimental Proce-
dures). In aph-1 mutant cells, the subcellular distribution
of aPKC was strikingly altered (Figure 7I). The cortical lo-
calization of aPKC was lost within the clone area, indicat-
ing that aph-1 is required for the proper localization of the
enzyme. Interestingly, analysis of the intracellular distri-
bution of PAR-1 using an antibody that recognizes total
PAR-1 protein, regardless of phosphorylated status,
showed that within aph-1 mutant clones, the bulk pool
of PAR-1was properly localized at the cell cortex (Fig-
ure 7J). However, similar labeling using the phospho-
specific anti-pT595-PAR-1 antibody revealed that this
phosphorylated form of PAR-1 is no longer detected
within aph-1 mutant cells, suggesting that aph-1 is
required specifically for phosphorylation of PAR-1 on
T595 or, alternatively, for the cortical accumulation of
T595-phosphorylated forms of PAR-1 (Figure 7K). A
complementary approach with anti-shaggy antibodies
did not detect any differences in shaggy protein levels
or its intracellular localization between wild-type and
aph-1 mutant cells (Figure 7L).
To further evaluate the effects of aph-1 on the intracel-
lular distribution of aPKC, we examined whether expres-
sion of the aph-1 transgene affected the intracellular
localization of this kinase. Expression of aph-1 under
the eye-specific GMR promoter caused an extraordinary
concentration of p-T595-PAR-1 labeling at the cell cor-
tex just beneath the plasma membrane (Figure 7M),
whereas shaggy intracellular localization was not no-
ticeably affected (Figure 7N). Collectively, these dataET
Rshow that aph-1 determines the localization of aPKC
at the cell cortex and that this effect is necessary for
aph-1-mediated regulation of PAR-1 activity and subse-
quent tau phosphorylation.
Discussion
A widely accepted view of AD pathogenesis, the ‘‘amy-
loid cascade hypothesis,’’ holds that the abnormal accu-
mulation of Ab triggers an intracellular signaling cascade
resulting in tau hyperphosphorylation, neurofibrillary
tangle formation, and, ultimately, neuronal dysfunction
and death (Hardy and Selkoe, 2002). However, it appears
that some cases of AD occur in the absence of b-amyloid
triggering pathology. This idea is supported by the
observation of FAD cases linked to loss-of-function mu-
tations in psn that nonetheless exhibit tau hyperphos-
phorylation and neuronal degeneration (Dermaut et al.,
2004; Marjaux et al., 2004). To investigate nonamyloido-
genic mechanisms that potentially contribute to AD
pathogenesis, we utilized Drosophila melanogaster, a
genetic model organism that possesses highly con-
served psn and g-secretase components but no APP
homologs capable of generating the Ab peptide (Luo
et al., 1990). We examined the effects caused by both
gene dosage reductions and transgenic expression of
individual fly g-secretase components and candidate
tau kinases in a sensitized genetic assay, in which trans-
genic expression of human tau produces a uniform but
easily modifiable retinal phenotype. This approach has
been widely used in Drosophila to investigate basic
signaling pathways as well as neurodegenerative dis-
ease mechanisms (Bilen and Bonini, 2005; Zoghbi and
Botas, 2002).
Using the Drosophila transgenic model, we demon-
strate that psn and its cofactors nct and aph-1 have an
essential role in preventing tau hyperphosphorylation
via regulation of independent PI3K/Akt/GSK3b and
aPKC/PAR-1 pathways. These conclusions are sup-
ported by the following observations: (1) gene dosage
reduction in psn and nct result in reduced levels of phos-
phorylated Akt and GSK3b at the inhibitory serine-9,
accompanied by increased tau phosphorylation. On
the other hand, aph-1 heterozygous flies exhibit low
levels of phosphorylated PAR-1 at the inhibitory threo-
nine-595 and increased tau phosphorylation at the
PAR-1-derived epitope 12E8; (2) ectopic expression of
CT
E(C and D) Removing one dose of PAR-1 suppresses the aph-1 mutant-induced tau eye phenotype in w; aph-1D35/par1W3; gl-tau/+ but does not
modify the nct mutation-induced tau phenotype in w; par1W3/+; gl-tau/nctJ1 (D).
(E and F) Removing one dose of nct in GMR-UAS-sgg/nctJ1, but not aph-1 in GMR-UAS-sgg/aph-1D35 flies (F), enhances the shaggy-induced
rough eye phenotype (compare to GMR-UAS-sgg in Figure 2A).
(G and H) Transgenic expression of aph-1 in GMR-UAS-sgg/nctJ1 flies does not modify their eye phenotype, whereas transgenic expression of
nct in GMR-UAS-sgg/nctJ1 flies suppresses the nct-associated tau toxicity (H).
(I–L) Eye phenotype produced by PAR-1 expression under the GMR promoter. Removing one copy of aph-1 from this genetic background in
GMR-UAS-Par1/aph-1D35 flies strongly enhances the phenotype (J) but equivalent reductions in either nct or psn have no detectable effect in
GMR-UAS-Par1/nctJ1 (K) and GMR-UAS-Par1/psnB3 flies (L).
(M–O) Transgenic expression of aph-1 suppresses the aph-1 mutant-induced phenotype in GMR-UAS-Par1/aph-1D35 flies (M), whereas equiv-
alent expression of nct (N) and psn (O) failed to modify the phenotype (compare to [J]).
(P) Western blot analysis comparing shaggy activation status in GMR-UAS-sgg/nctJ1, GMR-UAS-sgg/aph-1D35 flies, GMR-UAS-sgg/UAS-nct,
and GMR-UAS-sgg/UAS-aph-1. Anti-GSK3b antibodies are described in the legend to Figure 2; tubulin serves as the loading control; blot quan-
tification histograms are at right.
(Q) Western blot analysis of GMR-UAS-par1/UAS-aph-1, GMR-UAS-par1/UAS-nct, and GMR-UAS-par1/aph-1D35 head extracts with the PAR-
1T595 antibody, which recognizes PAR-1 phosphorylated at the inhibitory threonine-595; tubulin serves as the loading control; blot quantifica-
tion histograms are at right. Scale bars: (A)–(O), 100 mm. Mean 6 SEM, p < 0.001.
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371psn, nct, and aph-1 specifically rescues these pheno-
types; (3) reduction in GSK3b activity prevents psn and
nct-mediated tau toxicity, whereas increased activity of
PI3K or Akt suppresses it; (4) reduction in PAR-1 function
prevents aph-1-induced neurodegeneration, whereas
lowering the activity of aPKC, the putative PAR-1 inhibi-
tory kinase, counteracts this effect, implicating a distinct
regulatory pathway for aph-1; and (5) simple overexpres-
sion of psn, nct, or aph-1 prevents htau-induced neuro-
degeneration in the htau transgenic model (Figure S4).
Although overexpression of wild-type psn has previously
been shown to cause low levels of developmental apo-
ptosis in the fly retina, attributable to dominant-negative
interference with Notch signaling (Ye and Fortini, 1999),
these effects are strongly outweighed by the neuropro-
tective effects of psn on tau hyperphosphorylation.
What is the underlying biochemical mechanism for
these effects? Through studies on the subcellular distri-
butions of the relevant kinases in various genetic condi-
tions, we found that psn and nct control the intracellular
distribution of GSK3b, whereas aph-1 is required to pre-
serve the normal distribution of aPKC and the phosphor-
ylated form of PAR-1 at the cell cortex. It is unclear
whether these effects involve direct associations be-
tween psn, nct, aph-1, and the identified kinases or if
they are mediated by other proteins. Interestingly, our
rescue studies indicate that the cytoplasmic loop region
of psn, which is altered in the DE9 mutant, is functionally
important in terms of tau phosphorylation, and this loop
region is known to interact with several putative psn-
associated factors (Koo and Kopan, 2004; Menendez,
2004).
These kinase-regulatory functions of psn, nct, and
aph-1 are apparently independent of their traditional
role in g-secretase cleavage, as deduced from the fact
that the well-characterized aspartyl mutants of psn,
which lack catalytic protease activity, are still functional
with respect to regulation of tau phosphorylation. In
support of this concept, drug treatment of flies with
two different g-secretase aspartyl protease inhibitors
failed to affect tau phosphorylation or the activation sta-
tus of shaggy (see also Baki et al. [2004]). The equivalent
phenotypes we observed for psn and nct loss-of-func-
tion alleles are also intriguing. It has been shown previ-
ously that Drosophila nct confers stability to mature
psn (Chung and Struhl, 2001; Hu et al., 2002; Lo´pez-
Schier and St Johnston, 2002), raising the possibility
that the tau hyperphosphorylation seen upon reducing
nct activity could actually be due to a secondary effect
on psn accumulation.
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RAThe modulatory effects psn, nct, or aph-1 on the tau
kinase pathways observed in our Drosophila studies
might be of particular relevance to the pathogenesis of
Alzheimer’s disease. Over 100 different FAD mutations
in PS1 and PS2 have now been identified, all of which
cause disease in an autosomal dominant manner (Hashi-
moto et al., 2004; St George-Hyslop and Petit, 2005). Al-
though it remains controversial whether this autosomal
dominant behavior reflects a toxic ‘‘gain-of-function’’ ac-
tivity or a haploinsufficient dosage-related mechanism,
several observations indicate that FAD mutations in pre-
senilin are loss-of-function mutations in some respects.
When various FAD mutations were genetically assessed
with multiple independent mouse and nematode trans-
genic models, they were found to act as partial loss-of-
function alleles (Baumeister et al., 1997; Davis et al.,
1998; Levitan et al., 1996; Qian et al., 1998). Moreover,
a PS1 FAD mutation has been identified that truncates
the protein and therefore most likely causes disease
through a haploinsufficient mechanism involving loss
of one functional gene copy (Tysoe et al., 1998). If, as
these findings indicate, loss of one dose of presenilin
contributes to Alzheimer’s disease pathogenesis, the
fact that similar gene dosage reductions in presenilin
and other g-secretase components lead to dysregula-
tion of tau kinase pathways raises the possibility that
these effects might be causally involved in disease de-
velopment. This idea is consistent with our observation
that an FAD-like presenilin mutant transgene, psnDE9,
is unable to rescue the tau phenotypes associated with
psn haploinsufficiency. Our findings also agree with
a previous study showing that three different PS1 FAD
mutations, includingDE9, have effects on neurite growth
and tau phosphorylation counter to those of wild-type
PS1 (Pigino et al., 2001). Nevertheless, it should be noted
that we cannot exclude the possibility that an unknown
function of these g-secretase components, perhaps re-
lated to cytoskeletal scaffolding processes or protein
trafficking, is affected by the gene dosage manipulations
and is responsible for the observed effects on tau kinase
pathways. Further investigation will be required to clarify
this issue, particularly in view of the apparent lack of
a requirement for the aspartyl protease activity of g-sec-
retase in regulating tau phosphorylation.
In conclusion, these data identify distinct roles for pre-
senilin and its cofactors nicastrin and aph-1 in the
organization of intracellular junctions. Furthermore, we
found that they protect against abnormal tau phosphor-
ylation levels in vivo through g-secretase-independent
regulation of the PI3K/Akt/GSK3b and aPKC/PAR-1
CT
EDFigure 6. Nicastrin Regulates Tau Phosphorylation via the PI3K/Akt Pathway
(A–D) Eye phenotypes of gl-htau/nctJ1/PI3KGOF (A), gl-htau/nctJ1/PI3KDN (B), gl-htau/nctJ1/AktGOF (C), and gl-htau/nctJ1/AktDA (D) showing
that expression of functional PI3K or Akt suppresses the tau-induced phenotype.
(E) Western blot analysis showing the activation status of Akt in nct and aph-1 mutants. Tubulin serves as the loading control; quantification
histograms are at right.
(F) Western blot analysis demonstrating that PI3K or Akt reduces the level of phosphorylation at the tau AT8 epitope. Tubulin serves as the
loading control; quantification histograms are at right.
(G–I) Confocal analysis of third instar larval eye discs labeled with the GSK3-b-pY216 antibody (right, G) or armadillo antibody (right, H) or aPKC
antibody (right, I) counterstained with phalloidin (left). In wild-type neuronal clusters (top, G), shaggy exhibits a pronounced punctate distribution
at the cell cortex, whereas in nct homozygous mutant clones, shaggy is cytoplasmic (bottom, G). Localizations of armadillo and aPKC are not
altered in the nct mutant compared to wild-type (center and right, G).
(J and K) Nct transgene expression causes shaggy to accumulate more noticeably at the cell cortex (J), whereas the distribution of the T595-
phosphorylated form of Par-1 is not significantly affected (K). Scale bars: (A)–(D), 100 mm; (G)–(K), 5 mm. Mean 6 SEM, p < 0.001.
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372Figure 7. Aph-1 Regulates Tau Phosphorylation via aPKC
(A–F) Eye phenotypes of gl-htau/aPKC LOF (A), gl-htau/aPKC DN (B), gl-htau/aphD35/AphGOF/aPKC LOF (C), Par1 GOF/aPKC (D), Par1GOF/
aPKC DN (E), and Par1GOF/aphD35/aphGOF/aPKC LOF (F) showing that abrogated aPKC function strongly enhances the aph-1 mutant-induced
tau eye phenotype.
(G–H) Western blots demonstrating that mutations in aPKC enhance tau toxicity as revealed by elevated 12e8 epitope signal (G) and regulate
PAR-1 activation (H). Tubulin serves as the loading control.
(I–L) Confocal analysis of third instar larval eye discs labeled with antibodies recognizing aPKC (I), MARK (which detects total PAR-1) (J), PAR-
1T595 (K), and GSK3-b-pY216 (L), counterstained for LacZ to reveal mutant cell clonal territories. In aph-1 homozygous mutant clones (lacking
LacZ signal), aPKC is not detected at its normal cortical distribution (I), whereas MARK is properly localized (J). The phosphorylated form of
PAR-1 recognized by antibody PAR-1T595 loses its normal cortical localization within aph-1 mutant clones (K), whereas shaggy/GSK3b main-
tains its normal intracellular localization in the clones (L).
RE
TR
AC
TE
D
Presenilin Nicastrin or Aph1 Prevent Tau Toxicity
373kinase pathways (Figure 8). Our results suggest that ther-
apies aimed at treating or preventing Alzheimer’s dis-
ease through suppression of g-secretase activity should
also take into account possible alterations in the levels of
g-secretase complex components, which might lead to
potentially harmful effects on tau metabolism in neuronal
target tissues. Moreover, the experimental paradigm de-
scribed here may serve as a useful entry point to identify
genes or compounds capable of interfering with the
deleterious activities of GSK3b and PAR-1 in tau hyper-
phosphorylation and neurotoxicity.
Experimental Procedures
Genetics
PAR-1W3, UAS-PAR1, and APP-GV flies were generous gifts from
Drs. Daniel St. Johnston, Bingwei Lu, and Gary Struhl. The ey-FLP
system was used to generate homozygous mutant eyes (Newsome
et al., 2000). For heat-shock-induced recombinase, 24 hr old first
instar larvae were treated for 30 min at 38ºC.
Histology and Immunohistochemistry
Cryostat sectioning (10 mm) of adult heads was performed as de-
scribed previously (Jackson et al., 1998). Immunolabeling with
24B10 (1:50; Developmental Studies Hybridoma Bank) and AT100
antibody were followed by secondary antibody conjugated to horse-
radish peroxidase (HRP) and Alexa-red (1:100; Molecular Probes).
Figure 8. Mutations in g-Secretase Complex Components Contrib-
ute to Tau Pathology through Distinct g-Cleavage-Independent
Mechanisms
Reduced function of the g-secretase components psn, nct, and aph-1
leads to downregulation (downward arrows) of PI3K/Akt and aPKC
kinase activities, which in turn causes an upregulation (upward
arrows) in their respective downstream kinases GSK3b and PAR-1.
Increased activity of these tau kinases facilitates phosphorylation
of tau, promoting tau hyperphosphorylation, aggregation, and asso-
ciated neurotoxicity.
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tions: 24B10 (1:50), GSK3b-pY216 (1:100; Biosource International),
armadillo (1:50; Developmental Studies Hybridoma Bank), PAR-
1T595 (1:50), aPKC (1:100; Santa Cruz Biotechnology), LacZ
(1:500; ICN), and MARK (1:100) with an Alexa-conjugated secondary
antibody (1:100). Images were collected using a Leica confocal
microscope.
Quantification of Adult Eye Phenotypes
Adult eye roughness was calculated as a percentage of the total eye
surface by scoring images obtained by high-resolution light micros-
copy (w200 eyes scored/genotype).
Western Blot Analysis
Tau phosphorylation status was analyzed in adult fly heads homog-
enized in lysis buffer (10 mM Tris/HCl [pH 7.4], 150 mM NaCl, 5 mM
EDTA, 5 mM EGTA, 10% glycerol, 50 mM NaF, 1 mM NaVOF, 5 mM
DTT, 4 M Urea, and protease inhibitors). Proteins were resolved by
10% SDS-PAGE and probed with the following antibodies: 7.51
(1:100; provided by Dr. C.M. Wischik), 12E8 (1:1000; Elan Pharma-
ceuticals, provided by Dr. Seubert), AT8 (1:500; Innogenetics), tau1
(1:10000; Chemicon), PHF-1 (1:100; provided by Dr. P. Davies),
and AT100 (1:100; Innogenetics). Shaggy/GSK3b activation status
was monitored using GSK3b-pY216 (1:1000; Biosource International)
and GSK3b-pS9 (1:1000; Cell Signaling Technology). Activation sta-
tus of Akt and PAR1 was determined with p-Akt (1:1000; Cell Signal-
ing) and p-PAR1-T595 (1:1000) (see Hurov et al. [2004]). An antibody
against a-tubulin (1:5000; Amersham) was used for loading controls.
Sarcosyl extraction was performed as previously described
(Wittmann et al., 2001). Western blots were incubated with HRP-
labeled secondary antibodies (Amersham) and signals quantitated
by densitometry of autoradiograms with the ImageJ program.
Sample signals were normalized against 7.51 antibody or a-tubulin
signal. Graphics represent three different experiments.
Pharmacological Inhibition of g-Secretase
Flies were treated with DAPT and Compound E as described (Mic-
chelli et al., 2003). 200 ml of a 1 mM stock solution was added to
2 ml food vials prior to egg laying, and progeny were allowed to
develop in the presence of drug or DMSO only (as a control) until
eclosion. Adult progeny were heat shocked for 1 hr at 37ºC, placed
at 25ºC for 12 hr to allow expression of GFP, and examined by
fluorescence microscopy to assess relative levels of GFP expres-
sion.
Supplemental Data
The Supplemental Data for this article can be found online at http://
www.neuron.org/cgi/content/full/50/3/359/DC1/.
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CT
ED(M) Transgenic aph-1 expression leads to a more pronounced accumulation of phosphorylated PAR-1 at the cell cortex (compare to Figure 6K,
top), whereas the shaggy/GSK3b distribution is apparently unaffected (N) (compare to Figure 6J, top). Scale bars: (A)–(F), 100 mm; (I)–(N), 5 mm.
Mean 6 SEM, p < 0.001.
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